Abstract
Hypersensitivity pneumonitis (HP) is an immunologically mediated form of lung disease, resulting from inhalational exposure to a large variety of antigens. A subgroup of patients with fibrotic HP develops symptomatic, functional, and radiographic disease progression. Mortality occurs primarily from respiratory failure as a result of progressive and self-sustaining lung injury that often occurs despite immunosuppression and removal of the inciting antigen.
The development and validation of a prognostic transcriptomic signature for fibrotic HP (PREDICT-HP) is an observational multicenter cohort study designed to explore a transcriptomic signature from peripheral blood mononuclear cells in patients with fibrotic HP that is predictive of disease progression.
This article describes the design and rationale for the PREDICT-HP study.
This study will enroll approximately 135 patients with fibrotic HP at approximately seven academic medical sites.
Participants with a confirmed diagnosis of fibrotic HP are followed over 24 months and undergo physical examinations, self-administered questionnaires, chest computed tomography, pulmonary function tests, 6-minute walk and blood testing for transcriptomic analyses. At each 6-month follow-up visit the study will assess the participant's clinical course and clinical events including hospitalizations and respiratory exacerbations.
The PREDICT study has the potential to enhance our ability to predict disease progression and fundamentally advance our understanding of the pathobiology of FHP disease progression.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received August 27, 2023.
- Accepted October 17, 2023.
- Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
